Jounce Therapeutics Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Jounce Therapeutics stock.
View analyst ratings for Jounce Therapeutics or view top-rated stocks.

Wall Street analysts have given Jounce Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Jounce Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Jounce Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,090,000 shares, an increase of 76.2% from the February 28th total of 618,500 shares. Based on an average daily volume of 557,900 shares, the short-interest ratio is presently 2.0 days. Currently, 4.0% of the shares of the company are sold short.
View Jounce Therapeutics' Short Interest.

Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Jounce Therapeutics.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) issued its quarterly earnings data on Thursday, February, 25th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.50.
View Jounce Therapeutics' earnings history.

Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, JNCE shares have increased by 112.4% and is now trading at $9.09.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued 12-month target prices for Jounce Therapeutics' stock. Their forecasts range from $12.00 to $20.00. On average, they expect Jounce Therapeutics' share price to reach $15.50 in the next year. This suggests a possible upside of 70.5% from the stock's current price.
View analysts' price targets for Jounce Therapeutics or view top-rated stocks among Wall Street analysts.

45 employees have rated Jounce Therapeutics CEO Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among Jounce Therapeutics' employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Jounce Therapeutics include Sangamo Therapeutics (SGMO), Immunovant (IMVT), REGENXBIO (RGNX), AlloVir (ALVR), Translate Bio (TBIO), Alector (ALEC), C4 Therapeutics (CCCC), Replimune Group (REPL), Forma Therapeutics (FMTX), Mesoblast (MESO), Cortexyme (CRTX), Atara Biotherapeutics (ATRA), Ocugen (OCGN), Scholar Rock (SRRK) and Coherus BioSciences (CHRS).
View all of JNCE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR).

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JNCE stock can currently be purchased for approximately $9.09.

Jounce Therapeutics has a market capitalization of $412.63 million and generates $147.87 million in revenue each year. The company earns $56.82 million in net income (profit) each year or $1.66 on an earnings per share basis.

Jounce Therapeutics employs 128 workers across the globe.

The official website for Jounce Therapeutics is www.jouncetx.com.

Jounce Therapeutics is headquartered at 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.